Natco Pharma Secures In-Principle Stock Exchange Approvals for Rights Issue
Natco Pharma Ltd 路 Rights Issue 路 22 Sept 2026, 4:14 am
Natco Pharma Secures In-Principle Stock Exchange Approvals for Rights Issue Natco Pharma Limited received in-principle approval from both the National Stock Exchange of India and BSE Limited on 21st Sep'26 for its proposed rights issue of fully paid-up equity shares. This regulatory clearance represents a key procedural milestone, enabling the company to advance its equity capital-raising process.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet 路 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 路 14 Nov 2026
- Q2 FY27 Earnings Presentation 路 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 路 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Outcome of Board Meeting 路 13 Nov 2026
- Intimation of schedule of Concall 路 13 Nov 2026
